Research graph
References from Multidimensional in vitro assay for antimalarial combination testing and pharmacodynamic modeling – the MULT-i2 assay. Local targets link to admitted publications; unresolved targets remain external evidence.
A machine learning approach to define antimalarial drug action from heterogeneous cell-based screens
10.1126/sciadv.aba9338 · 2020 · External reference
Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35
10.1021/acsmedchemlett.0c00272 · 2020 · External reference
Ways to fit a PK model with some data below the quantification limit
10.1023/a:1012299115260 · 2001 · External reference
New and simplified method for drug combination studies by checkerboard assay
10.1016/j.mex.2021.101543 · 2021 · External reference
Handling data below the limit of quantification in mixed effect models
10.1208/s12248-009-9112-5 · 2009 · External reference
A repetitive antigen of Plasmodium falciparum that is homologous to heat shock protein 70 of Drosophila melanogaster
10.1073/pnas.83.22.8713 · 1986 · External reference
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
10.1038/nm.4381 · 2017 · External reference
The Toxicity Of Poisons Applied Jointly1
10.1111/j.1744-7348.1939.tb06990.x · 1939 · External reference
Development and application of a positive-negative selectable marker system for use in reverse genetics in Plasmodium
10.1093/nar/gnj033 · 2006 · External reference
A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum
10.1002/anie.202514085 · 2025 · External reference
Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations
10.1208/s12248-018-0239-0 · 2018 · External reference
Robust inducible Cre recombinase activity in the human malaria parasite Plasmodium falciparum enables efficient gene deletion within a single asexual erythrocytic growth cycle
10.1111/mmi.12206 · 2013 · External reference
Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda
10.1056/nejmoa2211803 · 2023 · External reference
Review of pyronaridine anti-malarial properties and product characteristics
10.1186/1475-2875-11-270 · 2012 · External reference
Malaria
10.1056/nejmra2405313 · 2025 · External reference
Processing of Plasmodium falciparum Merozoite Surface Protein MSP1 Activates a Spectrin-Binding Function Enabling Parasite Egress from RBCs
10.1016/j.chom.2015.09.007 · 2015 · External reference
Quantification of Plasmodium falciparum HPR-2 as an alternative method to [3H]hypoxanthine incorporation to measure the parasite reduction ratio in vitro
10.1016/j.ijantimicag.2023.106894 · 2023 · External reference
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites
10.1371/journal.pmed.1001169 · 2012 · External reference
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
10.1128/mbio.00303-17 · 2017 · External reference
Artemisinin and multidrug-resistant Plasmodium falciparum - a threat for malaria control and elimination
10.1097/qco.0000000000000766 · 2021 · External reference
Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system
10.1038/nbt.2925 · 2014 · External reference
Opening a Gateway for Chemiluminescence Cell Imaging: Distinctive Methodology for Design of Bright Chemiluminescent Dioxetane Probes
10.1021/acscentsci.7b00058 · 2017 · External reference
BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum
10.1007/bf01923455 · 1994 · External reference
Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
10.1016/s1473-3099(20)30929-4 · 2021 · External reference
Remarkable Enhancement of Chemiluminescent Signal by Dioxetane-Fluorophore Conjugates: Turn-ON Chemiluminescence Probes with Color Modulation for Sensing and Imaging
10.1021/jacs.6b09173 · 2016 · External reference
A Glowing Trajectory between Bio- and Chemiluminescence: From Luciferin-Based Probes to Triggerable Dioxetanes
10.1002/anie.201706969 · 2017 · External reference
Recent Advances and Challenges in Luminescent Imaging: Bright Outlook for Chemiluminescence of Dioxetanes in Water
10.1021/acscentsci.9b00372 · 2019 · External reference
Culture of human malaria parasites Plasmodium falciparum
10.1038/263767a0 · 1976 · External reference
Using Next Generation Chemiluminescent Probes to Improve the Plasmodium falciparum in vitro Parasite Reduction Ratio (PRR) Assay
10.1021/acsinfecdis.5c00924 · 2026 · External reference
Next Generation Chemiluminescent Probes for Antimalarial Drug Discovery
10.1021/acsinfecdis.3c00707 · 2024 · External reference
Antimalarial Quinoline Drugs Inhibit β-Hematin and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases
10.1038/s41598-019-51604-z · 2019 · External reference
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models
10.2165/00003088-198106060-00002 · 1981 · External reference
A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites
10.1016/0001-706x(93)90083-n · 1993 · External reference
A versatile strategy for rapid conditional genome engineering using loxP sites in a small synthetic intron in Plasmodium falciparum
10.1038/srep21800 · 2016 · External reference
Generating conditional gene knockouts in Plasmodium - a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9
10.1038/s41598-017-03984-3 · 2017 · External reference
Optimized Rhombic Experimental Dynamic Checkerboard Designs to Elucidate Pharmacodynamic Drug Interactions of Antibiotics
10.1007/s11095-022-03396-7 · 2022 · External reference
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
10.4269/ajtmh.1996.54.62 · 1996 · External reference
A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds
10.1038/srep16414 · 2015 · External reference
Towards clinically relevant dose ratios for Cabamiquine and Pyronaridine combination using P. falciparum field isolate data
10.1038/s41467-024-51994-3 · 2024 · External reference
Clinically applicable parasite viability assay for rapid assessment of antimalarial pharmacodynamic endpoints
10.1128/aac.01863-24 · 2025 · External reference
Drug susceptibility testing methods of antimalarial agents
10.4103/2229-5070.248695 · 2018 · External reference
A rapid and robust selection procedure for generating drug-selectable marker-free recombinant malaria parasites
10.1038/srep04760 · 2014 · External reference
Antimalarial Drug Resistance: A Threat to Malaria Elimination
10.1101/cshperspect.a025619 · 2017 · External reference
MitoTracker: A useful tool in need of better alternatives
10.1016/j.ejcb.2023.151371 · 2023 · External reference
Drug Combination Modeling: Methods and Applications in Drug Development
10.1002/jcph.2128 · 2023 · External reference
Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors
10.1093/cid/ciw388 · 2016 · External reference
Plasmodial HSP70s are functionally adapted to the malaria parasite life cycle
10.3389/fmolb.2015.00034 · 2015 · External reference
Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
10.1128/aac.00114-22 · 2022 · External reference
Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination
10.1186/s12936-015-0718-z · 2015 · External reference
Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans
10.1093/infdis/jiaa678 · 2021 · External reference
An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines [Review]
10.3389/fphar.2017.00158 · 2017 · External reference
The emergence of artemisinin partial resistance in Africa: how do we respond?
10.1016/s1473-3099(24)00141-5 · 2024 · External reference
P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action
10.1371/journal.pone.0030949 · 2012 · External reference
Development in Assay Methods for in Vitro Antimalarial Drug Efficacy Testing: A Systematic Review
10.3389/fphar.2017.00754 · 2017 · External reference
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models
10.1016/j.exppara.2006.09.016 · 2007 · External reference
A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil
10.1128/aac.43.6.1334 · 1999 · External reference
A Novel Tool for the Generation of Conditional Knockouts To Study Gene Function across the Plasmodium falciparum Life Cycle
10.1128/mbio.01170-19 · 2019 · External reference
Human malaria parasites in continuous culture
10.1126/science.781840 · 1976 · External reference
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
10.1016/s1473-3099(19)30391-3 · 2019 · External reference
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
10.1016/s0140-6736(20)30552-3 · 2020 · External reference
In vitro activity of immunosuppressive drugs against Plasmodium falciparum
10.1186/1475-2875-13-476 · 2014 · External reference
A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria
10.1038/nature04407 · 2006 · External reference
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
10.3390/ph16020163 · 2023 · External reference
Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases
10.1016/j.bcp.2007.03.011 · 2007 · External reference
A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
10.1038/s41467-017-01929-y · 2017 · External reference
New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
10.1128/aac.00556-22 · 2022 · External reference
10.30875/9789287074560
10.30875/9789287074560 · 2025 · External reference
A Glowing Trajectory between Bio- and Chemiluminescence: From Luciferin-Based Probes to Triggerable Dioxetanes
10.1002/anie.201706969 · ExternalCitation · doi-reference
A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum
10.1002/anie.202514085 · ExternalCitation · doi-reference
Drug Combination Modeling: Methods and Applications in Drug Development
10.1002/jcph.2128 · ExternalCitation · doi-reference
BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum
10.1007/bf01923455 · ExternalCitation · doi-reference
Optimized Rhombic Experimental Dynamic Checkerboard Designs to Elucidate Pharmacodynamic Drug Interactions of Antibiotics
10.1007/s11095-022-03396-7 · ExternalCitation · doi-reference
A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites
10.1016/0001-706x(93)90083-n · ExternalCitation · doi-reference
Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases
10.1016/j.bcp.2007.03.011 · ExternalCitation · doi-reference
Processing of Plasmodium falciparum Merozoite Surface Protein MSP1 Activates a Spectrin-Binding Function Enabling Parasite Egress from RBCs
10.1016/j.chom.2015.09.007 · ExternalCitation · doi-reference
MitoTracker: A useful tool in need of better alternatives
10.1016/j.ejcb.2023.151371 · ExternalCitation · doi-reference
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models
10.1016/j.exppara.2006.09.016 · ExternalCitation · doi-reference
Quantification of Plasmodium falciparum HPR-2 as an alternative method to [3H]hypoxanthine incorporation to measure the parasite reduction ratio in vitro
10.1016/j.ijantimicag.2023.106894 · ExternalCitation · doi-reference
New and simplified method for drug combination studies by checkerboard assay
10.1016/j.mex.2021.101543 · ExternalCitation · doi-reference
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
10.1016/s0140-6736(20)30552-3 · ExternalCitation · doi-reference
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
10.1016/s1473-3099(19)30391-3 · ExternalCitation · doi-reference
Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
10.1016/s1473-3099(20)30929-4 · ExternalCitation · doi-reference
The emergence of artemisinin partial resistance in Africa: how do we respond?
10.1016/s1473-3099(24)00141-5 · ExternalCitation · doi-reference
Opening a Gateway for Chemiluminescence Cell Imaging: Distinctive Methodology for Design of Bright Chemiluminescent Dioxetane Probes
10.1021/acscentsci.7b00058 · ExternalCitation · doi-reference
Recent Advances and Challenges in Luminescent Imaging: Bright Outlook for Chemiluminescence of Dioxetanes in Water
10.1021/acscentsci.9b00372 · ExternalCitation · doi-reference
Next Generation Chemiluminescent Probes for Antimalarial Drug Discovery
10.1021/acsinfecdis.3c00707 · ExternalCitation · doi-reference
Using Next Generation Chemiluminescent Probes to Improve the Plasmodium falciparum in vitro Parasite Reduction Ratio (PRR) Assay
10.1021/acsinfecdis.5c00924 · ExternalCitation · doi-reference
Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35
10.1021/acsmedchemlett.0c00272 · ExternalCitation · doi-reference
Remarkable Enhancement of Chemiluminescent Signal by Dioxetane-Fluorophore Conjugates: Turn-ON Chemiluminescence Probes with Color Modulation for Sensing and Imaging
10.1021/jacs.6b09173 · ExternalCitation · doi-reference
Ways to fit a PK model with some data below the quantification limit
10.1023/a:1012299115260 · ExternalCitation · doi-reference
Culture of human malaria parasites Plasmodium falciparum
10.1038/263767a0 · ExternalCitation · doi-reference
A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria
10.1038/nature04407 · ExternalCitation · doi-reference
Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system
10.1038/nbt.2925 · ExternalCitation · doi-reference
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
10.1038/nm.4381 · ExternalCitation · doi-reference
A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
10.1038/s41467-017-01929-y · ExternalCitation · doi-reference
Towards clinically relevant dose ratios for Cabamiquine and Pyronaridine combination using P. falciparum field isolate data
10.1038/s41467-024-51994-3 · ExternalCitation · doi-reference
Generating conditional gene knockouts in Plasmodium - a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9
10.1038/s41598-017-03984-3 · ExternalCitation · doi-reference
Antimalarial Quinoline Drugs Inhibit β-Hematin and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases
10.1038/s41598-019-51604-z · ExternalCitation · doi-reference
A rapid and robust selection procedure for generating drug-selectable marker-free recombinant malaria parasites
10.1038/srep04760 · ExternalCitation · doi-reference
A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds
10.1038/srep16414 · ExternalCitation · doi-reference
A versatile strategy for rapid conditional genome engineering using loxP sites in a small synthetic intron in Plasmodium falciparum
10.1038/srep21800 · ExternalCitation · doi-reference
Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda
10.1056/nejmoa2211803 · ExternalCitation · doi-reference
Malaria
10.1056/nejmra2405313 · ExternalCitation · doi-reference
A repetitive antigen of Plasmodium falciparum that is homologous to heat shock protein 70 of Drosophila melanogaster
10.1073/pnas.83.22.8713 · ExternalCitation · doi-reference
Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors
10.1093/cid/ciw388 · ExternalCitation · doi-reference
Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans
10.1093/infdis/jiaa678 · ExternalCitation · doi-reference
Development and application of a positive-negative selectable marker system for use in reverse genetics in Plasmodium
10.1093/nar/gnj033 · ExternalCitation · doi-reference
Artemisinin and multidrug-resistant Plasmodium falciparum - a threat for malaria control and elimination
10.1097/qco.0000000000000766 · ExternalCitation · doi-reference
Antimalarial Drug Resistance: A Threat to Malaria Elimination
10.1101/cshperspect.a025619 · ExternalCitation · doi-reference
The Toxicity Of Poisons Applied Jointly1
10.1111/j.1744-7348.1939.tb06990.x · ExternalCitation · doi-reference
Robust inducible Cre recombinase activity in the human malaria parasite Plasmodium falciparum enables efficient gene deletion within a single asexual erythrocytic growth cycle
10.1111/mmi.12206 · ExternalCitation · doi-reference
A machine learning approach to define antimalarial drug action from heterogeneous cell-based screens
10.1126/sciadv.aba9338 · ExternalCitation · doi-reference
Human malaria parasites in continuous culture
10.1126/science.781840 · ExternalCitation · doi-reference
Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
10.1128/aac.00114-22 · ExternalCitation · doi-reference
New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
10.1128/aac.00556-22 · ExternalCitation · doi-reference
Clinically applicable parasite viability assay for rapid assessment of antimalarial pharmacodynamic endpoints
10.1128/aac.01863-24 · ExternalCitation · doi-reference
A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil
10.1128/aac.43.6.1334 · ExternalCitation · doi-reference
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
10.1128/mbio.00303-17 · ExternalCitation · doi-reference
A Novel Tool for the Generation of Conditional Knockouts To Study Gene Function across the Plasmodium falciparum Life Cycle
10.1128/mbio.01170-19 · ExternalCitation · doi-reference
Review of pyronaridine anti-malarial properties and product characteristics
10.1186/1475-2875-11-270 · ExternalCitation · doi-reference
In vitro activity of immunosuppressive drugs against Plasmodium falciparum
10.1186/1475-2875-13-476 · ExternalCitation · doi-reference
Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination
10.1186/s12936-015-0718-z · ExternalCitation · doi-reference
Handling data below the limit of quantification in mixed effect models
10.1208/s12248-009-9112-5 · ExternalCitation · doi-reference
Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations
10.1208/s12248-018-0239-0 · ExternalCitation · doi-reference
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites
10.1371/journal.pmed.1001169 · ExternalCitation · doi-reference
P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action
10.1371/journal.pone.0030949 · ExternalCitation · doi-reference
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models
10.2165/00003088-198106060-00002 · ExternalCitation · doi-reference
10.30875/9789287074560
10.30875/9789287074560 · ExternalCitation · doi-reference
Plasmodial HSP70s are functionally adapted to the malaria parasite life cycle
10.3389/fmolb.2015.00034 · ExternalCitation · doi-reference
An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines [Review]
10.3389/fphar.2017.00158 · ExternalCitation · doi-reference
Development in Assay Methods for in Vitro Antimalarial Drug Efficacy Testing: A Systematic Review
10.3389/fphar.2017.00754 · ExternalCitation · doi-reference
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
10.3390/ph16020163 · ExternalCitation · doi-reference
Drug susceptibility testing methods of antimalarial agents
10.4103/2229-5070.248695 · ExternalCitation · doi-reference
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
10.4269/ajtmh.1996.54.62 · ExternalCitation · doi-reference
